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Abstract 
 
Background/Aim. Different bone substitutes have been used 
for filling and reparation of intrabony defects. The aim of this 
study was to compare nanocrystalline material, biphasic calcium 
phosphate poly-DL-lactide-co-glycolide (BCP/PLGA) with de-
proteinised bovine bone (DPBB) and β-tricalcium phosphate (β-
TCP) in the treatment of periodontal intrabony defects. Meth-
ods. The study included 24 patients with bilateral, intrabony de-
fects in the region of the upper first and second premolar, and 
the upper first molar. On one side of the mouth, DPBB 
(BioOss®) was used to fill defects in upper premolars while β-
TCP (RTR®) was used for the upper first molar. BCP/PLGA 
was applied into periodontal defects of the upper premolars and 
upper first molar of the opposite side. Results. The comparison 
of the BCP/PLGA and the β-TCP group, 6 months following 
filling of defects, showed a statistically significant reduction of 
periodontal pocket depth (PPD) and the position of the cement-
enamel junction (CEJ) in the group with BCP/PLGA, when 
compared to the β-TCP group. The reduction of PPD and CEJ 
was similar in the groups treated with BCP/PLGA and DPBB. 
Conclusion. Significant reductions of PPD and CEJ were regis-
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Uvod/Cilj. Različiti koštani zamenici koriste se za punjenje i 
reparaciju infrakoštanih defekata. Cilj rada bio je da se uporedi 
nanokristalni materijal – bifazni kalcijum-fosfat poli-DL-laktid-
ko-glikolid (BCP/PLGA) sa deproteinizovanom goveđom kos-
ti (DPBB) i β-trikalcijum fosfatom (β-TCP) u terapiji humanih 
parodontalnih infrakoštanih defekata. Metode. U studiju su 
bilа uključenа 24 pacijenata sa bilateralnim, infrakoštanim defe-
ktima u regiji gornjeg prvog i drugog premolara i prvog gornjeg 
molara. Slučajnim izborom defekti su punjeni DPBB (BioOss®) 
– gornji premolar i β-TCP (RTR®) – prvi gornji molar. 
BCP/PLGA bio je postavljan u parodontalne defekte gornjih 
premolara i prvog gornjeg molara sa suprotne strane. Plak in-
deks (PI), indeks krvarenja gingive (BI), pozicija cementno-
gleđnog pripoja (CEJ) i dubina parodontalnog džepa (PPD) 
mereni su preoperativno i šest meseci nakon operacije. Rezul-
tati. Poređenjem BCP/PLGA i β-TCP grupe utvrđena je statis-
tički značajna redukcija PPD i CEJ šest meseci nakon operacije. 
Redukcija PPD i CEJ bila je slična u grupama koje su tretirane 
sa BCP/PLGA i DPBB. Zaključak. Značajno smanjenje PPD 





kost, resorpcija; kost, zamenici; hirurgija, oralna, procedure; 
biokompatibilni materijali; koloidi; lečenje, ishod.  
 
Introduction 
Modern periodontal therapy is based on the use of natural 
or synthetic biomaterials for the filling and reparation of 
intrabony defects. Different bone substitutes have been used 
for this purpose with various rates of success 1–3. Deproteinised 
bovine bone (DPBB) is considered the most tested bone sub-
stitute in periodontal surgery. It has been suggested that 
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DPBB possesses osteoconductive properties 4, allowing the 
fast attachment of osteoblasts and deposition of new bone 5. 
A significant reduction in depth of intrabony defects has be-
en observed after implantation of DPBB 6. Scabbia and 
Trombelli 7 have indicated that implantation of DPBB pro-
duced significant improvement in terms of cement-enamel 
junction (CEJ) and the reduction of periodontal pocket depth 
(PPD) of human intrabony defects.  
It has been shown that β-tricalcium phosphate (β-TCP) 
promotes osteogenesis and bone regeneration in intrabony de-
fects in dogs with no signs of inflammatory reaction 8. One of 
the major drawbacks of β-TCP is its rapid resorption. Jensen et 
al. 9 showed almost complete resorption of β-TCP, 8 weeks after 
filling osseous defects in minipigs. 
A new biocomposite material, biphasic calcium phosphate 
(BCP) poly-DL-lactide-co-glycolide (PLGA) – (BCP/PLGA), in 
which BCP granules are coated with bioresorbable PLGA 
polymer, was introduced as a bone substitute by Ignjatovic et 
al. 10. A high level of osseous regeneration was obtained when 
using BCP/PLGA to fill intrabony defects in 10 patients 10. Ra-
pid and strong osteoconductivity was observed after implantati-
on of hydroxyapatite PLGA (HAp/PLGA) for reparing critical 
size radius defects in rabbits 11.  
There is however no bone substitute material which 
provides complete regeneration of intrabony periodontal de-
fects. Until now, there has been no study that compared 
BCP/PLGA with other bone substitutes for filling of 
intrabony defects. The aim of this study was to evaluate the 
clinical outcome of a biocomposite material use of 
BCP/PLGA and to compare it with DPBB and β-TCP in the 
treatment of human periodontal intrabony defects. 
Methods 
Materials 
Aqueous calcium nitrate [Ca(NO3)2] solution was added to 
a solution of ammonium phosphate [(NH4)3PO4] at 50°C over a 
period of 60 min, while stirring at the rate of 100 rpm. The solu-
tion was then subjected to heat treatment for 60 min at 100°C. 
The obtained gel was dried at room temperature and calcined at 
1,100°C for 6 h. In our previous studies, we showed that the ob-
tained calcium phosphate powder consisted of HAp and β-TCP. 
Based on the previously described methodology, the mass con-
tent was calculated at 80% HAp and 20% β-TCP12. This type of 
calcium phosphate is called BCP and is used for the production 
of BCP/PLGA composite biomaterial 12. BCP powder, whose 
roentgenograms and microstructure were examined in our pre-
vious papers 13, was synthesized by precipitation. 
PLGA (50:50) (Sigma Chemical Company, USA) was 
used as a polymer component. Granules of BCP were added into 
completely dissolved polymer, in amounts of 80 mass%. The 
solution was mixed at the speed of 30 rpm, and then methanol 
was added. After solvent evaporation, the particles were dried at 
room temperature for 24 h. The resulting granules of 
BCP/PLGA composite biomaterial were sterilized by γ rays (25 
kGy) before use. 
For crystallites sizes of Hap from BCP/DLPLG the Riet-
veld method was used 14.  
Composite production via the solvent–nonsolvent procedu-
re provides a covering of BCP with PLGA polymer 12–15. 
Characterisations of materials 
Wide angle X-ray structural (WAXS) analysis of the 
BCP/PLGA composite biomaterial was carried out using a 
Philips PW 1710 diffractometer. Microstructure characteriza-
tion was carried out using a JSM 5300 scanning electron mic-
roscope. The particle size distribution of powders was measu-
red using a Mastersizer 2000 (Malvern Instruments Ltd.) and 
Shirocco dispersion unit.  
 
Patients selection and surgical procedure 
 
The study protocol was approved by the Ethical Commit-
tee of the Faculty of Dentistry, University of Belgrade (docu-
ment number 123/2). The study included 24 patients, 14 
women and 10 men, suffering from severe periodontal disease. 
The patients included in the study signed informed consent 
forms. The inclusion criteria were: otherwise healthy patients 
(ASA I) between 18–45 years of age who were non-smokers, 
and had not undergone any dental treatment in the last 2 
weeks. The study exclusion criteria included: nursing mothers, 
pregnant women, those using any contraceptive medication or 
methods and patients using any analgesic agents within 24 h of 
the treatment. In addition, every patient had bilateral, three-
wall, intrabony defects in the region of the upper first and se-
cond premolar, and upper first molar, ≥  than 4 mm deep. This 
was a randomized, split mouth study, which included three 
groups: the group I – study group, (open flap debridement + 
BCP/PLGA), and two control groups: the group II (open flap 
debridement + deproteinised bovine bone, DPBB), and the 
group III – (open flap debridement + β-TCP). The intrabony 
defects were located on both the mesial and distal sides of the 
upper premolars and first molars.  
The operative procedure started after local anaesthesia 
consisting of 2% lidocaine with adrenaline 1: 80 000 
(Xylonor®, Septodont, France) was applied. The incision was 
intrasulcular and full thickness mucoperiosteal flaps at both 
vestibular and palatal sides were raised in order to expose enti-
re intrabony defects. All granulation tissue was removed from 
intrabony defects and the roots were completely scaled and 
planed by hand and ultrasonic instruments. 
After the open flap debridement was carried out, intrabony 
defects on the mesiopalatal or disto-palatal side of the upper 
premolars on one side of the mouth were filled with DPBB (Bi-
oOss®, Geistlich, Wolhausen, Switzerland), while β-TCP 
(RTR®, Septodont, France) was used on the mesiopalatal or dis-
to-palatal side of the upper first molar. During the same appoin-
tment, BCP/PLGA was applied into periodontal defects of the 
upper premolars and upper first molar of the opposite side of the 
mouth. The implanted material was firmly packed into intrabony 
defects with a sterile amalgam rammer. Finally, the mucoperios-
teal flaps were repositioned and sutured primarily with single in-
terdental sutures (Ethicon®, Mersilk 4-0, USA). 
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The plaque index (PI), bleeding index (BI), position of 
the cement-enamel junction (CEJ) and PPD were recorded 
preoperatively as well as 6 months after the operation. All the 
measurements were made by the same investigator using the 
same type of manual periodontal probe (PCP 12, Hu-Friedy, 
Chicago, IL, USA) with a probe tip diameter of 0.4 mm. The 
PI was scored as: score 0 for no plaque; score 1 for a film of 
plaque adhering to the free gingival margin and adjacent area 
of the tooth, which cannot be seen with the naked eye, but only 
by using a disclosing solution or probe; score 2 for moderate 
accumulation of deposits within the gingival pocket, on the 
gingival margin and/or adjacent tooth surface, which can be 
seen with the naked eye; and score 3 for abundat soft matter 
within the gingival pocket and/or on the tooth and gingival 
margin. The BI was also registered before the treatment and 6 
months following the operation and scored as: score 0 for no 
bleeding; score 1 for a single discreet bleeding point; score 2 
for several isolated bleeding points or a single line of blood 
appears; score 3 where the interdental triangle fills with blood 
shortly after probing; and score 4 for profuse bleeding occur-
ring after probing with blood flowing immediately into the 
marginal sulcus. 
One month before the operative procedure, basic perio-
dontal therapy, which included motivation and oral hygiene 
instructions as well as scaling and root planning with perio-
dontal probes, was administered. In addition, where traumatic 
interdental contact was present, occlusal corrections were car-
ried out. Furthermore, all inadequate fillings were replaced at 
least a month before. 
Antibiotic therapy (Amoksicilin®, Galenika, Beograd, 
Serbia) was prescribed for one week postoperatively. Detailed 




Statistical analysis was carried out using IBM SPSS for 
Windows (version 19.0). The continuous variables, such as 
CEJ and PPD, were shown as a mean ± SD. On the other hand, 
variables such as PI and BI were presented as category variab-
les. The significance of differences for PI and BI between ba-
seline and 6-month data, and between the groups 6 months 
following the treatment, was evaluated with a χ2-test. The sig-
nificance of differences for CEJ and PPD between baseline 
and the 6-month period was evaluated using the Wilcoxon test, 
while the Man Whitney U-test was used to determine differen-
ces for CEJ and PPD between groups 6 months after the treat-
ment. The level of significance was set at p < 0.05.  
Results 
Figure 1a shows the X-ray diffraction (XRD) patterns of 
BCP/PLGA composite biomaterials. The most intense peaks at 
2θ = 29°(2 1 0) and 31.8°(2 1 1) originate from HAp and that 
at 2θ = 31° (0 2 10) from (β-TCP). The crystallites sizes of 
HAp from BCP/DLPLG obtained from the XRD patterns were 
98 nm.  
Figure 1b shows a scanning electron microscope (SEM) 
image of the BCP/PLGA composite obtained according to 
experimental procedure. BCP granules are coated with the 
polymer and their average diameter is about 100 µm.  
Dry powder of BCP/PLGA was analyzed with the aim of 
establishing particle size distribution. Figure 1c) shows the par-
ticle size distributions for BCP/PLGA powder: d10 = 1.519 μm; 
d50 = 100.973 μm and d90 = 464.050 μm. The highest and the 
most important present fraction (d50) has particles with the dia-
meter of 100 μm. The results of particle size distribution are in 
accordance with SEM studies (Figure 1.b). Only 10% of all par-
ticles (d10) have a maximum diameter of 1.52 μm. 
 
Fig. 1 – a) X-ray diffraction pattern of biphasic calcium 
phosphate/poly-DL-lactide-co-glycolide; b) Scanning 
electron microscope image of BCP/PLGA; c) Particle size 
distributions of BCP/PLGA. 
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Table 1 
Comparison of plaque index (PI) before the treatment and 6 months after the operation 
Teeth, n (%) Tooth/Time of record Score  0 Score 1 Score 2 Score 3 Total p (χ
2 test) 
16 baseline - 14 (58.3) 8 (33.3) 2 (8.3) 24 (100) 
16 after BCP/ PLGA 17 (70.8) 7 (29.2) - - < 0.0001* 24 (100) 
15 baseline  - 14 (58.3) 8 (33.3) 2 (8.3) 24 (100) 
15  after  BCP/ PLGA 17 (70.8) 7 (29.2) - - < 0.0001* 24 (100) 
14 baseline - 14 (58.3) 8 (33.3) 2 (8.3) 24 (100) 
14  after BCP/ PLGA 17 (70.8) 7 (29.2) - - < 0.0001* 24 (100) 
24 baseline - 11 (45.8) 11 (45.8) 2 (8.3) 24 (100) 
24 after DPBB 18 (75.0) 6 (25.0) - - < 0.0001* 24 (100) 
25 baseline - 11 (45.8) 11 (45.8) 2 (8.3) 24 (100) 
25 after DPBB 18 (75.0) 6 (25.0) - - < 0.0001* 24 (100) 
26 baseline - 11 (45.8) 11 (45.8) 2 (8.3) 24 (100) 
26 after β-TCP 18 (75.0) 6 (25.0) - - < 0.0001* 24 (100) 
*Statistically significant difference; BCP/PLGA – biphasic calcium phosphate/poly-DL-lactide-co-glycolide.  
DPBB – deproteinised bovine bone; β-TCP – β-tricalcium phosphate. 
Score: 0 – no plaque; 1 – a film of plaque adhering to the free gingival margin and adjacent area of the tooth, seen only by using a 
disclosing solution or probe; 2 – moderate accumulation of deposits within the gingival pocket, on the gingival margin and/or ad-




Comparison of bleeding index (BI) before the treatment and 6 months after the operation 
Teeth, n (%) Tooth/Time of record Score 0 Score 1 Score 2 Score 3 Total             p (χ
2 test) 
16 baseline 1 (4.2) 9 (37.5) 7 (29.2) 7 (29.2) 24 (100) 
16 after BCP/ PLGA 10 (41.7) 14 (58.3) - - < 0.0001* 24 (100) 
15 baseline 1 (4.2) 7 (29.2) 11 (45.8) 5 (20.8) 24 (100) 
15 after BCP/ PLGA 10 (41.7) 13 (54.2) 1 (4.2) - < 0.0001* 24 (100) 
14 baseline 1 (4.2) 9 (37.5) 9 (37.5) 5 (20.8) 24 (100) 
14 after BCP/ PLGA 12 (50.0) 12 (50.0) - - < 0.0001* 24 (100) 
24 baseline 1 (4.2) 8 (33.3) 10 (41.7) 5 (20.8) 24 (100) 
24 after DPBB 13 (54.2) 11 (45.8) - - < 0.0001* 24 (100) 
25 baseline 1 (4.2) 6 (25.0) 10 (41.7) 7 (29.2) 24 (100) 
25 after DPBB 12 (50.0) 12 (50.0) - - < 0.0001* 24 (100) 
26 baseline 1 (4.2) 8 (33.3) 9 (37.5) 6 (25.0) 24 (100) 
26 after β-TCP 11 (45.8) 13 (54.2) - - < 0.0001* 
The PI and BI were significantly lower in all the three 
tested groups 6 months following the operation when compa-
red to preoperative values (Tables 1 and 2). There were no 
tested teeth with the BI score of 4 before the treatment or 6 
months following the operation. 
The results of this study also demonstrated statistically 
significant reduction in PPD and CEJ in all the three tested 
groups, 6 months following the treatment (Figure 2). 
The comparison of BCP/PLGA and β-TCP, 6 months 
following filling of defects, showed a statistically significant re-
24 (100) 
For abbreviations see under Table 1; 
 
 
Fig. 2 – Reduction in periodontal pocket depth (PPD) and the cemento-enamel junction (CEJ) 6 months following the operation (d – 
distal side; m – mesial side; * – statistically significant; p < 0.0001). BCP/PLGA – biphasic calcium phosphate/poly-DL-lactide-co-
glycolide.
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Fig. 4 – Filling the intrabony defect with biphasic calcium 
phosphate/poly-DL-lactide-co-glycolide (BCP/PLGA): a) X-
ray image before the treatment; b) Clinical appearance of 
intrabony defect; c) Intraoperative view of intrabony defect; 
d) Applied BCP/PLGA; e) Sutured reconstruction; f) X-ray 
image after 6 months. 
duction of PPD and CEJ in the group with BCP/PLGA, when 
compared to the β-TCP group (Figure 3). The reduction in PPD 
and CEJ was similar in groups treated with BCP/PLGA and 
DPBB (Figure 3). 
 
 
Fig. 3 – Comparison of periodontal pocket depth and level of 
cemento-enamel junction six months following the operation 
between tested groups (d – distal side; m – mesial side;* – statis-
tically significant; p < 0.0001). BCP/PLGA – biphasic calcium 
phosphate/poly-DL-lactide-co-glycolide. TCP – beta-tricalcium 
phosphate; DPBB – deproteinised bovine bone. 
 
Figure 4 shows one of 24 cases in this study. Figure 4a 
shows the intrabony defect on the mesial side of the upper first 
molar on X-ray film before the operation. Figure 4b shows the 
clinical appearance of the intrabony defect before the treat-
ment and Figure 4c demonstrates the intraoperative view of 
the same defect. The defect was filled with BCP/PLGA 
powder (Figure 4d). After reconstruction, the mucoperiostal 
flap was sutured with silk (Figure 4e). In the retroalveolar X-
ray image, made 6 months after intervention, the new-formed 
bone in the defect on the mesial side of upper first molar is ob-
vious (Figure 4f). 
Discussion 
The results of this study indicate that BCP/PLGA was 
more successful than β-TCP in periodontal intrabony defects 
filling when assessed six months following the treatment. In 
comparison to DPBB, the results obtained with BCP/PLGA 
were slightly better in terms of PPD and CEJ level reduction, 
but did not differ statistically. The improvement in PPD and 
CEJ obtained with the nanocrystalline bone substitute 
BCP/PLGA, could possibly be explained by its structure. 
XRD patterns show no peaks for PLGA polymer because 
this polymer is amorphous, which is in accordance with the 
XRD studies of PLGA of our previous research 13, 15. BCP 
coated with polylactide polymer enables protein adhesion 
prior to cell adhesion to the proteins on biomaterial 16, 17. It 
was shown that free surface energy decreased by adding 
BCP to the polymer component, and, consequently, allowed 
better interaction with surrounding cells 18. Likewise, the bet-
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ter results realised with BCP/PLGA in comparison to β-TCP 
could be explained by the preventive effect of the polymer 
component against removal by the immune system 19. In ad-
dition, it was already shown that BCP/PLGA enhanced oste-
oblast differentiation and production of alkaline phosphatase 
as a sign of its activity 12. 
Implantation of β-TCP into intrabony defects demons-
trated a significant reduction in PPD and CEJ after 6 months 
when compared to baseline levels. The results of our study 
are consistent with those of Saini et al. 20 who have demons-
trated significant clinical improvement in the treatment of 
human intrabony defects filled with β-TCP. Neamat et al. 8 in 
the study on dogs’ periodontal intrabony defects showed that 
β-TCP promoted osteogenesis and bone regeneration. On the 
other hand, our results obtained with β-TCP were not as po-
sitive as those achieved with BCP/PLGA. A possible 
explanation could be β-TCP’s rapid resorption. Due to the 
initial progressive degradation phase and the accumulation of 
phagocytising cells accompanying degradation of the materi-
al, the implant particles may not integrate with the bone 21.  
Our results showed that PPD and CEJ were similarly 
reduced after filling intrabony defects with DPBB and 
BCP/PLGA. This is in accordance with the study of Kim and 
Kim 22 who presented similar bone formation after using 
DPBB and HAp/PLGA in critical size rat calvarial defects. 
The studies with Biooss® as a bone substitute showed 
intrabony defect filling and reduction of PPD 6, as well as os-
seous regeneration around dental implants 4. Cordaro et al. 23 
showed that bone-to-graft contact was greater with DPBB 
compared to β-TCP (48% vs 34% respectively), and, accor-
ding to this finding, it can be concluded that DPBB has the 
higher osteoconductivity. Although we did not directly com-
pare DPBB and β-TCP, good results obtained with DPBB as 
well as with BCP/PLGA may be explained by higher 
osteoconductivity than that achieved by β-TCP.  Resorption 
of DPBB particles still remains a controversial issue. DPBB 
seems to be inert and stable over time and to remain 
sequestered in bone, marrow, and fibrovascular tissue (for up 
to 10 years) 24. Schlegel and Donath 25 showed histological 
signs of DPBB particles 6 years following bone defects fill. 
On the other hand, Thaller et al. 26 demonstrated resorption 
of DPBB, which underwent normal physiologic bone remo-
delling in the rabbit calvarial model.  
We found clinical and statistical improvement in terms of 
PPD and CEJ reduction in all the three groups 6 months 
following the operation. These results, obtained with each of the 
bone substitutes, are likely to be a consequence of the three-wall 
anatomy of intra-bony defects. The findings could be explained 
by the rich blood supply and growth factors deriving from each 
of three bony walls. This is in accordance with the study of El-
legaard and Löe 27, who reported that defect resolution was grea-
ter in a three-wall defect site than that in two-wall defects. 
It is interesting to note that PI and BI showed statistically 
significant improvement 6 months following implantation of 
each bone substitute. The explanation for this may be better oral 
hygiene, closely connected with the reduction of PPD and CEJ. 
Conclusion 
The results of the present study indicate that both nano-
crystalline biphasic calcium phosphate/poly-DL-lactide-co-
glycolide and deproteinised bovine bone grafting biomaterials 
have clinically and statistically significant improvement in 
terms of cemento-enamel junction gain and periodontal pockel 
depth reduction when used for the treatment of intraosseous 
defects. In addition, it should be emphasised that (BCP/PLGA) 
demonstrated clinically and statistically significant reduction 
of periodontal pockel depth and cemento-enamel junction le-
vels when compared to β-tricalcium phosphate 6 months 
following the treatment. 
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